The Recovery in Core Laboratories N.V.'s Results Accelerated in the Second Quarter
The recovery in Core Laboratories' (NYSE: CLB) financial results continued gaining momentum during the second quarter, with revenue and earnings both climbing by double digits. But the overall results were mixed, since revenue came in below the company's guidance range while earnings hit the high end of its forecast. Further, the company sees the market entering a transitional period in the upcoming quarters, which will slow down its recovery.
Metric
Q2 2017
Source: Fool.com
Core Laboratories Inc. Aktie
15,00 €
0,67 %
Leichtes Sell-Übergewicht bei Core Laboratories Inc. mit 3 Sell- gegenüber 0 Buy-Einschätzungen.
Ein negatives, wenn auch nicht starkes, Potenzial für Core Laboratories Inc. mit einem Kursziel von 14 € im Vergleich zu 15.0 €.
